Market Intelligence, Clinical Progress, and High-Purity Reagents for Reproductive Oncology & Endocrine Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GNRHR (Gonadotropin-releasing hormone receptor) drug discovery. As a Class A GPCR central to reproductive endocrinology, GNRHR requires conformationally intact reagents for meaningful assay outcomes. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Cell Line Tool | GNRHR Full-Length Lentivirus Premade Particles. High titer, HEK293 optimized. Sequence Verified. Endotoxin Controlled. | View GNRHR Products |
| Gene Delivery | GNRHR Lentivirus Particles & Promise-ORF Cloning Vector. Full-length ORF with native Kozak signal. GFP reporter available. Sequence Verified. | View GNRHR Products |
| Antigen | GNRHR ECD-Fc Fusion Protein & Extracellular Loops-Fc. High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. | View GNRHR Products |
| Benchmark Ab | Anti-GNRHR Monoclonal Antibody (Research Grade), including Degarelix-competitive clone. Recombinant positive control for flow cytometry, IF, and binding assays. Sequence Verified. | View GNRHR Products |
| Validator | GNRHR siRNA Set (3 unique sequences). For knockdown verification and specificity controls in calcium flux and functional assays. | View GNRHR Products |
| Related Target: GNRH1 | Gonadotropin-releasing hormone 1 (Ligand). High purity decapeptide & precursor protein. Natural peptide for receptor binding and competition assays. | View GNRH1 Products |
| Related Target: FSHR | Follicle-stimulating hormone receptor. Downstream effector in the hypothalamic-pituitary-gonadal axis. HEK293 expressed (native glycosylation). | View FSHR Products |
| Related Target: LHCGR | Luteinizing hormone/choriogonadotropin receptor. Parallel signaling node; heterodimerization partner in pituitary cells. Critical for selectivity counter-screening. | View LHCGR Products |
| Related Target: KISS1R | Kisspeptin receptor (GPR54). Upstream regulatory GPCR controlling GNRHR expression levels. | View KISS1R Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Native GPCR Conformation & Membrane Integration | Full-length GNRHR lentivirus generates stable HEK293 cell lines with native glycosylation, correct topology, and Gq/11 coupling for functional readouts (cAMP, calcium flux). |
| Cross-species Preclinical Translation (Cyno/Mouse) | Human, Cynomolgus, and Mouse ortholog ORF and proteins available (>95% purity); sequence verified for epitope conservation and translational assay alignment. |
| Internalization Kinetics (Antagonist mode) | Live-cell imaging compatible lentivirus: GFP-tagged GNRHR for real-time trafficking studies and β-arrestin recruitment assays. |
| Specificity Control (Off-target GPCR screening) | Validated siRNA set and homolog panel (LHCGR, FSHR, OXTR) for target-specific signal verification; clinical benchmark antibodies for epitope mapping. |
| Lack of Reliable Assay Controls | Clinical Benchmark Antibodies (engineered to compete with Degarelix and Elagolix binding) included for precise assay standardization. |
Live GNRHR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- View Active Clinical Trials (General)
- View Active Clinical Trials (Prostate Cancer)
- View Active Clinical Trials (Endometriosis)
- Latest Resistance Research
- Recent Patent Filings
- Recent Patent Filings (Small Molecule)
Global Clinical Landscape & Future Outlook
The race for GNRHR therapeutics is intensifying, with major players shifting focus from injectable peptide agonists and antagonists to oral non-peptide small-molecule antagonists. As first-generation oral antagonists (relugolix, elagolix) reach blockbuster status in endometriosis and prostate cancer, the next wave of R&D is targeting tissue-selective signaling profiles, long-acting depot formulations, and combination add-back regimens that minimize bone-density loss and hot-flush side effects. Concurrently, GNRHR-directed ADCs (Antibody-Drug Conjugates) and targeted radioligand therapies are emerging, capitalizing on GNRHR overexpression in specific reproductive tract tumors. The field is also exploring biased signaling modulation to decouple central hypothalamic effects from peripheral gonadal suppression, potentially revolutionizing endometriosis management with bone-sparing profiles.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Non-peptide Oral Antagonist | AbbVie, Myovant (Sumitovant), Pfizer, Takeda, ObsEva | Endometriosis, Uterine Fibroids, Prostate Cancer | High-throughput Calcium Flux / cAMP Assay (Need stable GNRHR-expressing cell lines via Lentivirus) |
| Peptide Antagonist (Injectable) | Ferring, Astellas, Paladin/Bioprojet | Advanced Prostate Cancer, IVF | Radioligand Binding Competition (Need high-purity membrane preps from lentivirus cells) |
| Peptide Agonist (LHRH Agonist) | AbbVie, Ipsen, AstraZeneca, Takeda | Prostate Cancer, Central Precocious Puberty | Receptor Desensitization / Internalization Kinetics (Need flow-validated GNRHR+ cells) |
| Biosimilar / Biobetter Peptide | Teva, Sandoz and other generics | Same as originators | Comparative Binding & Sequence Fidelity (Need sequence verified comparator reagents) |
| Tissue-Selective Modulator | Bayer, AstraZeneca | Endometriosis (with bone sparing) | Biased Signaling Panel (Need mutant GNRHR variants for specific pathway analysis) |
| ADC / Radioligand | Emerging Biotechs | Ovarian & Endometrial Cancers | Internalization Assay (Need high-purity ECD and stable cell lines) |
| Bispecific / mAb | Preclinical Pipelines | Solid Tumors | Binding Affinity (Requires high-purity target antigens) |
Genetic Variants in GNRHR
Key mutations associated with hypogonadotropic hypogonadism (HH7) include:
- rs10489 (Arg → Gln): Retains GnRH binding but with reduced affinity in vitro.
- rs774317793: Associated with HH7.
- rs886907903: Associated with HH7.
Evidence source: UniProt P30968.